The European Patent Office (EPO) has granted a new CRISPR/Cas9 patent (EP 4 289 948) to Professor Charpentier, along with The Regents of the University of California and the University of Vienna (collectively known as CVC). The divisional patent includes broad independent claims covering single guide RNAs, modified DNA-targeting RNAs… Read More
ERS Genomics and not-for-profit Medicines Discovery Catapult (MDC) have signed a non-exclusive commercial-use CRISPR license agreement. The partnership hopes to combine ERS’s CRISPR/Cas9 patent portfolio with MDC’s expertise and technology. As part of the deal, MDC and its partners will benefit from access to ERS’ CRISPR/Cas9 portfolio – the foundational… Read More
ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio. StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for… Read More
